Intervention not reported
All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality secondary to infection within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality secondary to thromboembolism within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (within 30 days post‐surgery) · adults undergoing inguinal and femoral hernia repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Postoperative mortality (within 30 days from surgery) · patients with resectable disease
1 finding from 1 review
Intervention not reported
Postoperative mortality (within 30 days from surgery) · patients with resectable disease
The intervention leads to higher postoperative mortality (within 30 days from surgery) (high certainty).
1 finding from 1 review
Early postoperative mortality Deaths in the 30 days after surgery · patients with refractory angina
Transmyocardial laser revascularization showed no clear difference in early postoperative mortality Deaths in the 30 days after surgery compared with medical treatment (high certainty).
1 finding from 1 review
Perinatal mortality · Pregnant women considered to have periodontal disease (gingivitis or periodontitis) after dental examination
It is very uncertain whether periodontal treatment (scaling and root planing, polishing, or… changes perinatal mortality (including fetal and neonatal deaths up to the… compared with no treatment (very low certainty).
1 finding from 1 review
Mortality (up to 90 days) · cancer surgery
It is very uncertain whether cell salvage changes mortality (up to 90 days) compared with no cell salvage (very low certainty).
1 finding from 1 review
Mortality (0 to 30 days) · adult cardiac surgical patients
Epidural analgesia showed no clear difference in mortality (0 to 30 days) compared with systemic analgesia (low certainty).
1 finding from 1 review
Mortality (0 to 30 days) · adults undergoing cardiac surgery without cardiopulmonary bypass
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality rate at 30 days · adults having abdominal surgery
Epidural analgesia showed no clear difference in all‐cause mortality rate at 30 days compared with intravenous patient‐controlled analgesia (low certainty).
1 finding from 1 review
All‐cause mortality (up to 30 days) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (up to 30 days) compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality (within 30 days) · adults undergoing cardiac surgery under general anaesthesia
The intervention showed no clear difference in all‐cause mortality (within 30 days) (low certainty).
1 finding from 1 review
Short‐term mortality (up to 30 days) · Neonates, children and adults undergoing cardiovascular surgery
1 finding from 1 review